SMS Lifesciences India Limited (SMSLIFE.NS)
INR 1179.0
(-0.08%)
INR 1179.0
(-0.08%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1 Billion INR | 15.78% |
| 2022 | 869.97 Million INR | 9.3% |
| 2021 | 795.97 Million INR | 23.05% |
| 2020 | 646.85 Million INR | 0.16% |
| 2019 | 645.85 Million INR | 37.14% |
| 2018 | 470.93 Million INR | 72.17% |
| 2017 | 273.53 Million INR | 4.36% |
| 2016 | 262.1 Million INR | -26.04% |
| 2015 | 354.39 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 1 Billion INR | 15.78% |
| 2023 Q4 | 1 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 951.66 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q2 | 910.52 Million INR | 0.0% |
| 2022 FY | 869.97 Million INR | 9.3% |
| 2022 Q4 | 869.97 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q2 | 647.45 Million INR | 0.0% |
| 2021 Q4 | 795.97 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 795.97 Million INR | 23.05% |
| 2020 Q2 | 714.61 Million INR | 0.0% |
| 2020 FY | 646.85 Million INR | 0.16% |
| 2020 Q4 | 646.85 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 479.81 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 645.85 Million INR | 37.14% |
| 2019 Q4 | 645.85 Million INR | 0.0% |
| 2018 FY | 470.93 Million INR | 72.17% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 470.93 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 256.13 Million INR | 0.0% |
| 2017 FY | 273.53 Million INR | 4.36% |
| 2017 Q2 | 194.67 Million INR | 0.0% |
| 2017 Q4 | 273.53 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 262.1 Million INR | -26.04% |
| 2016 Q4 | 262.1 Million INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2015 FY | 354.39 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Biocon Limited | 162.76 Billion INR | 99.381% |
| Blue Jet Healthcare Limited | 16.12 Million INR | -6144.501% |
| Concord Biotech Limited | 97.37 Million INR | -934.38% |
| Dishman Carbogen Amcis Limited | 23.12 Billion INR | 95.645% |
| Jubilant Ingrevia Limited | 7.4 Billion INR | 86.393% |
| Lyka Labs Limited | 586.5 Million INR | -71.737% |
| Panacea Biotec Limited | 209.9 Million INR | -379.866% |
| Piramal Pharma Limited | 47.1 Billion INR | 97.862% |
| Supriya Lifescience Limited | 54.88 Million INR | -1735.346% |
| Syngene International Limited | 5.55 Billion INR | 81.858% |
| TAKE Solutions Limited | 370.85 Million INR | -171.603% |
| Zota Health Care Limited | 952.84 Million INR | -5.708% |